Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06609148 · ClinicalTrials.gov registry record · NA
Probiotic in Patients With Bile Acid Malabsorption/Diarrhea
A NA study of Bile Acid Malabsorption and Bile Acid Diarrhea, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06609148: Recruiting NA study of Bile Acid Malabsorption and Bile Acid Diarrhea, sponsored by Mayo Clinic.
NCT06609148 is a NA study of Bile Acid Malabsorption and Bile Acid Diarrhea that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06609148, a NA study of Bile Acid Malabsorption and Bile Acid Diarrhea, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to assess effect of the DSF probiotic on fecal bile acid levels in patients with BAM.
Primary Outcome
Reported as micromoles per g stool and % primary bile acids
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT De Simone formulation probiotic
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-01-02 |
| Est. Completion | 2026-03-30 |
| Phase | NA |
What NCT06609148 shows while recruiting
NCT06609148 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 2 conditions, with Bile Acid Malabsorption appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06609148 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06609148 about?
NCT06609148 is a clinical study titled "Probiotic in Patients With Bile Acid Malabsorption/Diarrhea". The purpose of this study is to assess effect of the DSF probiotic on fecal bile acid levels in patients with BAM.
What is the current status of trial NCT06609148?
This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2025-01-02. Estimated completion is 2026-03-30.
What conditions does trial NCT06609148 study?
This clinical trial studies the following conditions: Bile Acid Malabsorption, Bile Acid Diarrhea.
What interventions are being tested in trial NCT06609148?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), De Simone formulation probiotic (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06609148?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06609148 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06609148's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI